32 patents
Utility
Treatment of congenital adrenal hyperplasia
22 Aug 23
CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
Dimitri E. Grigoriadis
Filed: 20 Oct 20
Utility
Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors
8 Aug 23
Nicole Harriott, Nicholas Pagano, Byron A. Boon
Filed: 12 Jan 23
Utility
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
1 Aug 23
Graham Beaton, Mi Chen, Timothy Richard Coon, Todd Ewing, Wanlong Jiang, Willy Moree, Martin Rowbottom, Warren Wade, Liren Zhao, Richard Lowe, Nicole Smith, Neil Ashweek, Yun-Fei Zhu
Filed: 18 Dec 20
Utility
Methods for the administration of certain VMAT2 inhibitors
23 May 23
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,1 1b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered digoxin.
Christopher F. O'Brien, Haig P. Bozigian
Filed: 20 Oct 20
Utility
Processes for the preparation of uracil derivatives
4 Oct 22
The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof.
Donald J. Gallagher, Laszlo R. Treiber, Robert Michael Hughes, Onorato Campopiano, Peng Wang, Yuxin Zhao, Shine K. Chou, Michael Allen Ouellette, Donald Nicholas Hettinger
Filed: 10 Jan 20
Utility
Methods for the administration of certain VMAT2 inhibitors
13 Sep 22
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1, 3,4, 6,7,11 b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is a CYP2D6 poor metabolizer.
Christopher F. O'Brien, Haig P. Bozigian
Filed: 26 Oct 20
Utility
High dosage valbenazine formulation and compositions, methods, and kits related thereto
26 Apr 22
Solid pharmaceutical compositions with high drug loading are provided.
Richard Alexander Moore, Jr., Gregory A. McClelland, Christopher F. O'Brien
Filed: 19 Oct 20
Utility
Treatment of congenital adrenal hyperplasia
26 Apr 22
CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
Dimitri E. Grigoriadis
Filed: 4 Aug 21
Utility
[9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
6 Jul 21
Neil Ashweek, Nicole Harriott
Filed: 22 Jan 20
Utility
Methods for the administration of certain VMAT2 inhibitors
22 Jun 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 2D6 (CYP2D6) inhibitor.
Christopher F. O'Brien, Haig P. Bozigian
Filed: 8 May 20
Utility
VMAT2 inhibitor compounds and compositions thereof
22 Jun 21
Nicole Harriott, Donald Hettinger, Shawn Branum, Jeffrey C. Culhane
Filed: 17 Apr 18
Utility
Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases
15 Jun 21
Nicole Harriott, Nicholas Pagano
Filed: 4 Nov 16
Utility
Methods for the administration of certain VMAT2 inhibitors
8 Jun 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof.
Grace S. Liang, Christopher F. O'Brien, Dao Tuyet Thai-Cuarto
Filed: 3 Aug 20
Utility
High dosage valbenazine formulation and compositions, methods, and kits related thereto
8 Jun 21
Solid pharmaceutical compositions with high drug loading are provided.
Richard Alexander Moore, Jr., Gregory A. McClelland, Christopher F. O{grave over ( )}Brien
Filed: 19 Oct 20
Utility
Substituted triazoles and methods relating thereto
1 Jun 21
Neil J. Ashweek, John P. Williams, Deborah Slee, Manisha Moorjani
Filed: 4 Jun 20
Utility
Methods for the administration of certain VMAT2 inhibitors
4 May 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient has mild, moderate, or severe hepatic impairment.
Christopher F. O'Brien, Haig P. Bozigian
Filed: 8 May 20
Utility
Methods for the administration of certain VMAT2 inhibitors
23 Mar 21
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-a-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
Christopher F. O'Brien, Haig P. Bozigian
Filed: 8 May 20
Utility
Methods for the administration of certain VMAT2 inhibitors
9 Mar 21
Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.
Gordon Raphael Loewen, Sha Rosa Luo
Filed: 10 Aug 20
Utility
Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
9 Mar 21
Graham Beaton, Mi Chen, Timothy Richard Coon, Todd Ewing, Wanlong Jiang, Willy Moree, Martin Rowbottom, Warren Wade, Liren Zhao, Richard Lowe, Nicole Smith, Neil Ashweek, Yun-Fei Zhu
Filed: 2 Jul 19
Utility
Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
16 Feb 21
Provided herein are processes for the preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.
Kevin McGee, Bin-Feng Li, Shawn Branum
Filed: 15 Jul 20